LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 484

Search options

  1. Article ; Online: Biomarker testing in patients with advanced non-small cell lung cancer: the never-ending story.

    Malapelle, Umberto / Novello, Silvia

    The Lancet regional health. Europe

    2024  Volume 38, Page(s) 100845

    Language English
    Publishing date 2024-03-01
    Publishing country England
    Document type Journal Article
    ISSN 2666-7762
    ISSN (online) 2666-7762
    DOI 10.1016/j.lanepe.2024.100845
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Should adjuvant treatment be offered to patients with stage IB non-small cell lung cancer?

    Passiglia, Francesco / Novello, Silvia

    EClinicalMedicine

    2023  Volume 57, Page(s) 101845

    Language English
    Publishing date 2023-02-06
    Publishing country England
    Document type Journal Article
    ISSN 2589-5370
    ISSN (online) 2589-5370
    DOI 10.1016/j.eclinm.2023.101845
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Interview: developing therapies for lung cancer.

    Novello, Silvia

    Lung cancer management

    2017  Volume 6, Issue 1, Page(s) 25–27

    Abstract: Silvia Novello speaks to Roshaine Wijayatunga, Managing Commissioning Editor: ...

    Abstract Silvia Novello speaks to Roshaine Wijayatunga, Managing Commissioning Editor:
    Language English
    Publishing date 2017-07-14
    Publishing country England
    Document type Journal Article
    ZDB-ID 2669715-4
    ISSN 1758-1974 ; 1758-1966
    ISSN (online) 1758-1974
    ISSN 1758-1966
    DOI 10.2217/lmt-2017-0007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Mismatch Repair Deficiency in Lung Tumors: Adding a New Layer of Complexity on Pie Slices.

    Cani, Massimiliano / Novello, Silvia / Bironzo, Paolo

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

    2023  Volume 19, Issue 3, Page(s) 363–365

    MeSH term(s) Humans ; Lung Neoplasms/genetics ; Colorectal Neoplasms ; Neoplastic Syndromes, Hereditary ; Brain Neoplasms
    Language English
    Publishing date 2023-11-22
    Publishing country United States
    Document type Editorial
    ZDB-ID 2432037-7
    ISSN 1556-1380 ; 1556-0864
    ISSN (online) 1556-1380
    ISSN 1556-0864
    DOI 10.1016/j.jtho.2023.11.023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6664: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 652: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going?

    Passiglia, Francesco / Novello, Silvia

    Translational lung cancer research

    2021  Volume 9, Issue 6, Page(s) 2518–2520

    Language English
    Publishing date 2021-01-19
    Publishing country China
    Document type Editorial
    ZDB-ID 2754335-3
    ISSN 2226-4477 ; 2218-6751
    ISSN (online) 2226-4477
    ISSN 2218-6751
    DOI 10.21037/tlcr-2019-cnsclc-14
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Lewy body-associated proteins: victims, instigators, or innocent bystanders? The case of AIMP2 and alpha-synuclein.

    Lashuel, Hilal A / Novello, Salvatore

    Neurobiology of disease

    2021  Volume 156, Page(s) 105417

    Abstract: Lewy bodies (LBs), one of the neuropathological defining hallmarks of Parkinson's disease (PD), are composed of a complex mixture of alpha-synuclein (aSyn) filaments and hundreds of proteins, lipids, and membranous organelles. However, these proteins' ... ...

    Abstract Lewy bodies (LBs), one of the neuropathological defining hallmarks of Parkinson's disease (PD), are composed of a complex mixture of alpha-synuclein (aSyn) filaments and hundreds of proteins, lipids, and membranous organelles. However, these proteins' role in aSyn aggregation and the biogenesis of LBs remains poorly understood. Previous studies have focused on investigating the role of these proteins as modifiers of aSyn aggregation, inclusion formation, and toxicity; very often, one protein at a time. In a recent study, Ham et al. suggest that one of these proteins, aminoacyl tRNA synthase complex-interacting multifunctional protein 2 (AIMP2), plays a primary role in the initiation of aSyn aggregation and is essential for aSyn inclusion formation and toxicity in cells and several models of synucleinopathies (Ham et al., 2020). Based on in vitro aggregation studies, they proposed a model in which AIMP2 self-associates to form amyloid-like aggregates that interact with monomeric aSyn and catalyze/seed the formation of aSyn fibrils and, eventually, LB-like inclusions. Herein, we present a critical analysis of their results and conclusions, review previous studies on AIMP2 aggregation, and reexamine the role of AIMP2 in regulating aSyn inclusion formation and clearance and aSyn-induced neurodegeneration in Parkinson's disease. We conclude by presenting lesson learned and recommendations on experimental factors and approaches that should be considered in future studies aimed at investigating the potential of targeting LBs-associated proteins, including AIMP2, for developing therapies to treat PD and other synucleinopathies.
    MeSH term(s) Animals ; Humans ; Lewy Bodies/genetics ; Lewy Bodies/metabolism ; Lewy Bodies/pathology ; Nuclear Proteins/genetics ; Nuclear Proteins/metabolism ; Protein Aggregation, Pathological/genetics ; Protein Aggregation, Pathological/metabolism ; Protein Aggregation, Pathological/pathology ; Substantia Nigra/metabolism ; Substantia Nigra/pathology ; alpha-Synuclein/genetics ; alpha-Synuclein/metabolism
    Chemical Substances AIMP2 protein, human ; Nuclear Proteins ; alpha-Synuclein
    Language English
    Publishing date 2021-06-06
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1211786-9
    ISSN 1095-953X ; 0969-9961
    ISSN (online) 1095-953X
    ISSN 0969-9961
    DOI 10.1016/j.nbd.2021.105417
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4444: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.

    Novello, Silvia / Califano, Raffaele / Reinmuth, Niels / Tamma, Antonella / Puri, Tarun

    The oncologist

    2023  Volume 28, Issue 5, Page(s) 402–413

    Abstract: The objective of this narrative review is to summarize the efficacy and safety of available therapies for rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), including in patients with central nervous system (CNS) ... ...

    Abstract The objective of this narrative review is to summarize the efficacy and safety of available therapies for rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), including in patients with central nervous system (CNS) metastases. Background information is provided on RET rearrangements in NSCLC and the molecular testing options available as well as an overview of clinical guidelines for molecular testing, which recommend broad molecular testing, including for RET rearrangements. The efficacy and safety of potential treatments for RET fusion-positive NSCLC, including multikinase inhibitors, RET-selective inhibitors, pemetrexed-based therapy, and immunotherapies are reviewed from Phase I/II and `real-world' studies, alongside an overview of primary and secondary resistance mechanisms. The RET-selective inhibitors, selpercatinib and pralsetinib, are preferred first-line therapy options for patients with RET fusion-positive metastatic NSCLC and are recommended as subsequent therapy if RET inhibitors have not been used in the first-line setting.
    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Proto-Oncogene Proteins c-ret/genetics ; Proto-Oncogene Proteins c-ret/therapeutic use ; Pemetrexed/therapeutic use ; Gene Rearrangement ; Protein Kinase Inhibitors/therapeutic use
    Chemical Substances Proto-Oncogene Proteins c-ret (EC 2.7.10.1) ; Pemetrexed (04Q9AIZ7NO) ; Protein Kinase Inhibitors ; RET protein, human (EC 2.7.10.1)
    Language English
    Publishing date 2023-02-23
    Publishing country England
    Document type Review ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1409038-7
    ISSN 1549-490X ; 1083-7159
    ISSN (online) 1549-490X
    ISSN 1083-7159
    DOI 10.1093/oncolo/oyac264
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4845: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 494: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer.

    Vavalà, Tiziana / Mariniello, Annapaola / Novello, Silvia

    Translational cancer research

    2022  Volume 8, Issue Suppl 1, Page(s) S48–S54

    Abstract: Lung cancer still represents the leading cause of cancer-related mortality. However, the recent advent of tyrosine kinase inhibitors (TKI), pioneering drugs against targetable mutations, have dramatically improved prognosis of advanced non-small cell ... ...

    Abstract Lung cancer still represents the leading cause of cancer-related mortality. However, the recent advent of tyrosine kinase inhibitors (TKI), pioneering drugs against targetable mutations, have dramatically improved prognosis of advanced non-small cell lung cancer (NSCLC) patients. Anaplastic lymphoma kinase (
    Language English
    Publishing date 2022-01-15
    Publishing country China
    Document type Journal Article ; Review
    ZDB-ID 2901601-0
    ISSN 2219-6803 ; 2218-676X
    ISSN (online) 2219-6803
    ISSN 2218-676X
    DOI 10.21037/tcr.2018.10.23
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now?

    Mecca, Caterina / Bertaglia, Valentina / Novello, Silvia

    Translational cancer research

    2022  Volume 8, Issue Suppl 2, Page(s) S79–S83

    Language English
    Publishing date 2022-01-15
    Publishing country China
    Document type Editorial ; Comment
    ZDB-ID 2901601-0
    ISSN 2219-6803 ; 2218-676X
    ISSN (online) 2219-6803
    ISSN 2218-676X
    DOI 10.21037/tcr.2018.08.23
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors As Adjuvant Therapy in Completely Resected Non-Small-Cell Lung Cancer.

    Novello, Silvia

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2015  Volume 33, Issue 34, Page(s) 3985–3986

    MeSH term(s) Antineoplastic Agents/therapeutic use ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Erlotinib Hydrochloride/therapeutic use ; Female ; Humans ; Lung Neoplasms/drug therapy ; Male
    Chemical Substances Antineoplastic Agents ; Erlotinib Hydrochloride (DA87705X9K)
    Language English
    Publishing date 2015-12-01
    Publishing country United States
    Document type Comment ; Editorial
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.2015.63.7587
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top